| methylphenidate extended release capsule / Generic mfg. |
NCT00301236: Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder |
|
|
| Completed | 3 | 252 | US | Dexmethylphenidate HCl extended-release capsules | Novartis | ADHD, ADD | | 11/06 | | |
NCT01269463: Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting |
|
|
| Completed | 3 | 26 | US | Methylphenidate Hydrochloride Extended Release Capsule, Biphentin®, Placebo, Biphentin placebo | Rhodes Pharmaceuticals, L.P. | Attention Deficit Hyperactivity Disorder, ADHD | 06/11 | 03/13 | | |
NCT01239030: Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD |
|
|
| Completed | 3 | 230 | US | Methylphenidate Hydrochloride Extended Release Capsules, Biphentin, Placebo, Placebo capsules | Rhodes Pharmaceuticals, L.P. | Attention Deficit Hyperactivity Disorder, ADHD | 02/12 | 03/12 | | |
NCT02139124: The Efficacy and Safety of PRC-063 in Adult ADHD Patients |
|
|
| Completed | 3 | 375 | Canada, US | Placebo, Placebo capsule, PRC-063 25 mg, 25 mg capsule, PRC-063 45 mg, 45 mg capsule, PRC-063 70 mg, 70 mg capsule, PRC-063 100 mg, 100 mg capsule | Rhodes Pharmaceuticals, L.P., Purdue Pharma, Canada | ADHD | 10/14 | 01/15 | | |
| Completed | 3 | 360 | US, Canada | Placebo, Placebo capsule, PRC-063 25 mg, 25 mg capsule, PRC-063 45 mg, 45 mg capsule, PRC-063 70 mg, 70 mg capsule, PRC-063 85 mg, 85 mg capsule | Rhodes Pharmaceuticals, L.P., Purdue Pharma LP | ADHD | 03/15 | 05/15 | | |
| Completed | 3 | 60 | US | PRC-063 25 mg, 25 mg capsule, Placebo, Placebo capsule, PRC-063 35 mg, 35 mg capsule, PRC-063 45 mg, 45 mg capsule, PRC-063 55 mg, 55 mg capsule, PRC-063 70 mg, 70 mg capsule, PRC-063 85 mg, 85 mg capsule, PRC-063 100 mg, 100 mg capsule | Rhodes Pharmaceuticals, L.P., Purdue Pharma LP | Attention Deficit Hyperactivity Disorder (ADHD) | 04/15 | 05/15 | | |
NCT02168127: Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD |
|
|
| Completed | 3 | 360 | US, Canada | Drug: PRC-063, Methylphenidate, PRC-063 | Rhodes Pharmaceuticals, L.P., Purdue Pharma LP | ADHD | 05/15 | 06/15 | | |
NCT02555150: A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD |
|
|
| Completed | 3 | 40 | US | PRC-063, lisdexamfetamine dimesylate, Placebo | Rhodes Pharmaceuticals, L.P., Purdue Pharma LP | Attention Deficit Hyperactivity Disorder | 01/17 | 01/17 | | |
NCT03172481: PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD |
|
|
| Completed | 3 | 156 | US | PRC-063 oral capsules, Placebo oral capsules | Purdue Pharma, Canada | ADHD | 08/17 | 12/17 | | |
NCT03618030: PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 3 | 288 | US | PRC-063 oral capsules, Placebo oral capsules | Purdue Pharma, Canada | ADHD | 07/19 | 07/19 | | |
NCT06431256: Ph3 Multicenter, 3wk RDBPC Efficacy, Safety & PK Study of Evening Dosed MPH HCl ER Capsules (HLD200) in Children 4-5 Yr With ADHD |
|
|
| Not yet recruiting | 3 | 168 | NA | HLD200 methylphenidate hydrochloride capsules, methylphenidate, Placebo HLD200 capsules, placebo | Ironshore Pharmaceuticals and Development, Inc | Attention Deficit Hyperactivity Disorder | 07/26 | 07/26 | | |
